Product Name | MF | CAS | Details |
---|
Metabolic system | Details |
Screening model of gastrointestinal motility inhibitors | Details |
Myocardial injury protective agent screening model | Details |
Screening model of renal protective agents | Details |
Reproductive toxicity and reproductive ability evaluation; Gonadal growth evaluation; Histological sections of gonads; | Details |
Gastrointestinal peristalsis function (autonomic nerve). | Details |
inflammatory reaction | Details |
Intestinal morphology; Intestinal peristalsis requires motor function. | Details |
Animal long-term toxicity test | Details |
Drug stability test | Details |
Apoptosis inhibitor screening model | Details |
Fat metabolism model | Details |
Erythrocyte thrombosis model | Details |
Mouse bradycardia model | Details |
Incidence of developmental toxicity and teratogenicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding) | Details |
Behavior (touch response, movement influence, light and dark influence); | Details |
Behavior | Details |
Anaphylactic reaction | Details |
neurotoxicity | Details |
Preclinical drug experiment preclinical research (outsourcing entrusted experiment) | Details |
Efficacy evaluation model of drug efficacy evaluation system | Details |
Mitochondrial function | Details |
Protective model of vascular endothelial injury | Details |
Promoting tissue regeneration / wound healing | Details |
Embryotoxicity (OECD standard) | Details |
Degree of liver degeneration; Yolk sac size. | Details |
Osteotoxicity | Details |
Phenotypic observation | Details |
Induction model of high sugar and high fat diet | Details |
Screening model of antialcoholic agents | Details |
Screening model of angiogenesis promoters | Details |
Cytochrome P450 analysis | Details |
Cartilage injury model | Details |
apoptotic cell | Details |
The incidence of renal capsule edema;. | Details |
Ocular toxicity | Details |
Mortality; Evaluation of median lethal concentration (LC50). | Details |
Animal analgesic model | Details |
Animal modeling technology service | Details |
Screening model of P-glycoprotein inhibitors | Details |
Screening model of energy metabolism regulator | Details |
Induced qi stagnation and blood stasis thrombosis model | Details |
Liver kidney model | Details |
Cardiovascular toxicity heart rate; Heart rhythm; The incidence of pericardial edema; Incidence of bleeding; Incidence of changes in blood flow velocity; Incidence of thrombosis | Details |
Fluorescence signal intensity of apoptotic cells in central nervous system; | Details |
Carcinogenicity (mice) | Details |
Tryptase expression level (OD value); Anaphylactic reaction test. | Details |
Screening model of bone development promoters | Details |
The incidence of egg coagulation; No heart rate; Hatching rate; The incidence of no somite formation; Incidence of tail non separation; | Details |
Nephrotoxicity | Details |
Bone mineral density (fluorescence signal intensity); Number of vertebrae. | Details |
Median lethal concentration | Details |
Skin irritation; Muscle texture; Quantification of skin apoptotic cells; Skin pigment changes. | Details |
Safety evaluation | Details |
Preclinical evaluation of antiviral research and development | Details |
Uric acid model | Details |
Intestinal digestive function | Details |
Skeletal muscle | Details |
Screening model of therapeutic agents for osteoporosis | Details |
Modeling animal | Details |
Induction model of caspase activity | Details |
Pharmacodynamic evaluation model of slimming drugs | Details |
Drug screening model for the treatment of heart failure | Details |
Screening model of hepatoprotective drugs | Details |
Number of hematotoxic neutrophils; Number of macrophages; Number of red blood cells (signal intensity); Blood flow. | Details |
Peripheral motor nerve length; Incidence of brain degeneration; | Details |
Macrophage function | Details |
Gastrointestinal toxicity | Details |
Animal hemostatic model | Details |
Animal movement model | Details |
Preclinical spinal cord injury experiment | Details |
Angiogenesis inhibitor screening | Details |
Hypolipidemic model | Details |
Platelet aggregation thrombosis model | Details |
Oxygen free radical (ROS) scavenger screening model | Details |
Incidence of acute toxicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding) | Details |
Vitellogenin (VTG) content detection; The expression of genes related to hypothalamic pituitary gonadal axis was detected. | Details |
Behavioral toxicity | Details |
Number of neutrophils; Expression level of inflammatory factors. | Details |
Drug evaluation and testing items (outsourcing entrusted experiment) | Details |
Preclinical evaluation of reproductive toxicity | Details |
Spleen yang deficiency model | Details |
Intestinal mucus secretion function | Details |
Analgesic drug screening | Details |
Drug safety evaluation model index | Details |
Hepatotoxicity (juvenile fish) | Details |
Fluorescence signal intensity of hair cells | Details |
Skin toxicity | Details |
Comet experiment; Genotoxicity evaluation. | Details |
Animal movement system model | Details |
Genotoxicity | Details |
Eye size; Ocular apoptotic cells; Ocular vascular area; Ocular histopathology. | Details |
Audiotoxicity | Details |
Fluorescence signal intensity of apoptotic cells (AO staining, TUNEL staining) | Details |
Animal hybridization experiment | Details |
PM2. 5. Screening model of drainage promoters | Details |
Cardio cerebrovascular | Details |
Anti angiogenesis model | Details |
Preclinical evaluation of cardiac drugs | Details |
Immunotoxicity | Details |
Product Total: Product Page: | ||||
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 |